# A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults

> **NCT03208101** · PHASE1 · COMPLETED · sponsor: **LG Chem** · enrollment: 42 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Poliomyelitis
- Hepatitis B
- Haemophilus Influenzae Type b Infection

## Interventions

- **BIOLOGICAL:** DTP-HepB-IPV-Hib vaccine
- **BIOLOGICAL:** DTP-HepB-Hib vaccine & IPV

## Key facts

- **NCT ID:** NCT03208101
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-03
- **Primary completion:** 2017-09-06
- **Final completion:** 2017-12-21
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03208101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03208101, "A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03208101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*